Importance of murine study design for testing toxicity of retroviral vectors in support of phase I trials

Elke Will, Jeff Bailey, Todd Schuesler, Ute Modlich, Brenden Balcik, Ben Burzynski, David Witte, Gerlinde Layh-Schmitt, Cornelia Rudolph, Brigitte Schlegelberger, Christof von Kalle, Christopher Baum, Brian P. Sorrentino, Lars M. Wagner, Patrick Kelly, Lilith Reeves, David A. Williams

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

Although retroviral vectors are one of the most widely used vehicles for gene transfer, there is no uniformly accepted pre-clinical model defined to assess their safety, in particular their risk related to insertional mutagenesis. In the murine pre-clinical study presented here, 40 test and 10 control mice were transplanted with ex vivo manipulated bone marrow cells to assess the long-term effects of the transduction of hematopoietic cells with the retroviral vector MSCV-MGMTP140K wc. Test mice had significant gene marking 8-12 months post-transplantation with an average of 0.93 vector copies per cell and 41.5% of peripheral blood cells expressing the transgene MGMTP140K, thus confirming persistent vector expression. Unexpectedly, six test mice developed malignant lymphoma. No vector was detected in the tumor cells of five animals with malignancies, indicating that the malignancies were not caused by insertional mutagenesis or MGMTP140K expression. Mice from a concurrent study with a different transgene also revealed additional cases of vector-negative lymphomas of host origin. We conclude that the background tumor formation in this mouse model complicates safety determination of retroviral vectors and propose an improved study design that we predict will increase the relevance and accuracy of interpretation of pre-clinical mouse studies.

Original languageEnglish (US)
Pages (from-to)782-791
Number of pages10
JournalMolecular Therapy
Volume15
Issue number4
DOIs
StatePublished - Apr 2007
Externally publishedYes

Fingerprint

Insertional Mutagenesis
Transgenes
Lymphoma
Neoplasms
Safety
Bone Marrow Cells
Genes
Blood Cells
Cohort Studies
Transplantation
Clinical Studies

ASJC Scopus subject areas

  • Molecular Biology

Cite this

Will, E., Bailey, J., Schuesler, T., Modlich, U., Balcik, B., Burzynski, B., ... Williams, D. A. (2007). Importance of murine study design for testing toxicity of retroviral vectors in support of phase I trials. Molecular Therapy, 15(4), 782-791. https://doi.org/10.1038/sj.mt.6300083

Importance of murine study design for testing toxicity of retroviral vectors in support of phase I trials. / Will, Elke; Bailey, Jeff; Schuesler, Todd; Modlich, Ute; Balcik, Brenden; Burzynski, Ben; Witte, David; Layh-Schmitt, Gerlinde; Rudolph, Cornelia; Schlegelberger, Brigitte; von Kalle, Christof; Baum, Christopher; Sorrentino, Brian P.; Wagner, Lars M.; Kelly, Patrick; Reeves, Lilith; Williams, David A.

In: Molecular Therapy, Vol. 15, No. 4, 04.2007, p. 782-791.

Research output: Contribution to journalArticle

Will, E, Bailey, J, Schuesler, T, Modlich, U, Balcik, B, Burzynski, B, Witte, D, Layh-Schmitt, G, Rudolph, C, Schlegelberger, B, von Kalle, C, Baum, C, Sorrentino, BP, Wagner, LM, Kelly, P, Reeves, L & Williams, DA 2007, 'Importance of murine study design for testing toxicity of retroviral vectors in support of phase I trials', Molecular Therapy, vol. 15, no. 4, pp. 782-791. https://doi.org/10.1038/sj.mt.6300083
Will, Elke ; Bailey, Jeff ; Schuesler, Todd ; Modlich, Ute ; Balcik, Brenden ; Burzynski, Ben ; Witte, David ; Layh-Schmitt, Gerlinde ; Rudolph, Cornelia ; Schlegelberger, Brigitte ; von Kalle, Christof ; Baum, Christopher ; Sorrentino, Brian P. ; Wagner, Lars M. ; Kelly, Patrick ; Reeves, Lilith ; Williams, David A. / Importance of murine study design for testing toxicity of retroviral vectors in support of phase I trials. In: Molecular Therapy. 2007 ; Vol. 15, No. 4. pp. 782-791.
@article{e967b6dbc79b45aa817a4c0f6ad42152,
title = "Importance of murine study design for testing toxicity of retroviral vectors in support of phase I trials",
abstract = "Although retroviral vectors are one of the most widely used vehicles for gene transfer, there is no uniformly accepted pre-clinical model defined to assess their safety, in particular their risk related to insertional mutagenesis. In the murine pre-clinical study presented here, 40 test and 10 control mice were transplanted with ex vivo manipulated bone marrow cells to assess the long-term effects of the transduction of hematopoietic cells with the retroviral vector MSCV-MGMTP140K wc. Test mice had significant gene marking 8-12 months post-transplantation with an average of 0.93 vector copies per cell and 41.5{\%} of peripheral blood cells expressing the transgene MGMTP140K, thus confirming persistent vector expression. Unexpectedly, six test mice developed malignant lymphoma. No vector was detected in the tumor cells of five animals with malignancies, indicating that the malignancies were not caused by insertional mutagenesis or MGMTP140K expression. Mice from a concurrent study with a different transgene also revealed additional cases of vector-negative lymphomas of host origin. We conclude that the background tumor formation in this mouse model complicates safety determination of retroviral vectors and propose an improved study design that we predict will increase the relevance and accuracy of interpretation of pre-clinical mouse studies.",
author = "Elke Will and Jeff Bailey and Todd Schuesler and Ute Modlich and Brenden Balcik and Ben Burzynski and David Witte and Gerlinde Layh-Schmitt and Cornelia Rudolph and Brigitte Schlegelberger and {von Kalle}, Christof and Christopher Baum and Sorrentino, {Brian P.} and Wagner, {Lars M.} and Patrick Kelly and Lilith Reeves and Williams, {David A.}",
year = "2007",
month = "4",
doi = "10.1038/sj.mt.6300083",
language = "English (US)",
volume = "15",
pages = "782--791",
journal = "Molecular Therapy",
issn = "1525-0016",
publisher = "Nature Publishing Group",
number = "4",

}

TY - JOUR

T1 - Importance of murine study design for testing toxicity of retroviral vectors in support of phase I trials

AU - Will, Elke

AU - Bailey, Jeff

AU - Schuesler, Todd

AU - Modlich, Ute

AU - Balcik, Brenden

AU - Burzynski, Ben

AU - Witte, David

AU - Layh-Schmitt, Gerlinde

AU - Rudolph, Cornelia

AU - Schlegelberger, Brigitte

AU - von Kalle, Christof

AU - Baum, Christopher

AU - Sorrentino, Brian P.

AU - Wagner, Lars M.

AU - Kelly, Patrick

AU - Reeves, Lilith

AU - Williams, David A.

PY - 2007/4

Y1 - 2007/4

N2 - Although retroviral vectors are one of the most widely used vehicles for gene transfer, there is no uniformly accepted pre-clinical model defined to assess their safety, in particular their risk related to insertional mutagenesis. In the murine pre-clinical study presented here, 40 test and 10 control mice were transplanted with ex vivo manipulated bone marrow cells to assess the long-term effects of the transduction of hematopoietic cells with the retroviral vector MSCV-MGMTP140K wc. Test mice had significant gene marking 8-12 months post-transplantation with an average of 0.93 vector copies per cell and 41.5% of peripheral blood cells expressing the transgene MGMTP140K, thus confirming persistent vector expression. Unexpectedly, six test mice developed malignant lymphoma. No vector was detected in the tumor cells of five animals with malignancies, indicating that the malignancies were not caused by insertional mutagenesis or MGMTP140K expression. Mice from a concurrent study with a different transgene also revealed additional cases of vector-negative lymphomas of host origin. We conclude that the background tumor formation in this mouse model complicates safety determination of retroviral vectors and propose an improved study design that we predict will increase the relevance and accuracy of interpretation of pre-clinical mouse studies.

AB - Although retroviral vectors are one of the most widely used vehicles for gene transfer, there is no uniformly accepted pre-clinical model defined to assess their safety, in particular their risk related to insertional mutagenesis. In the murine pre-clinical study presented here, 40 test and 10 control mice were transplanted with ex vivo manipulated bone marrow cells to assess the long-term effects of the transduction of hematopoietic cells with the retroviral vector MSCV-MGMTP140K wc. Test mice had significant gene marking 8-12 months post-transplantation with an average of 0.93 vector copies per cell and 41.5% of peripheral blood cells expressing the transgene MGMTP140K, thus confirming persistent vector expression. Unexpectedly, six test mice developed malignant lymphoma. No vector was detected in the tumor cells of five animals with malignancies, indicating that the malignancies were not caused by insertional mutagenesis or MGMTP140K expression. Mice from a concurrent study with a different transgene also revealed additional cases of vector-negative lymphomas of host origin. We conclude that the background tumor formation in this mouse model complicates safety determination of retroviral vectors and propose an improved study design that we predict will increase the relevance and accuracy of interpretation of pre-clinical mouse studies.

UR - http://www.scopus.com/inward/record.url?scp=33947210723&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33947210723&partnerID=8YFLogxK

U2 - 10.1038/sj.mt.6300083

DO - 10.1038/sj.mt.6300083

M3 - Article

C2 - 17299409

AN - SCOPUS:33947210723

VL - 15

SP - 782

EP - 791

JO - Molecular Therapy

JF - Molecular Therapy

SN - 1525-0016

IS - 4

ER -